Apogee Therapeutics (APGE) Operating Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Operating Expenses data on file, last reported at $82.8 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 31.18% year-over-year to $82.8 million in Q1 2026; TTM through Mar 2026 was $305.3 million, a 26.26% increase from a year earlier, with the FY2025 full-year figure at $285.6 million, up 31.69% from the prior year.
• Operating Expenses for Q1 2026 stood at $82.8 million, up from $78.1 million in the prior quarter.
• Over the last five years, Operating Expenses for APGE reached as high as $82.8 million in Q1 2026 and fell as low as $1.8 million in Q2 2022.
• Historically, Operating Expenses has averaged $44.0 million across 5 years, with a median of $41.2 million in 2024.
• Across the five-year window, Operating Expenses surged 939.92% in 2023 and grew 2.87% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $14.1 million in 2022, then surged by 163.53% to $37.2 million in 2023, then jumped by 104.23% to $75.9 million in 2024, then increased by 2.87% to $78.1 million in 2025, then grew by 6.04% to $82.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $82.8 million in Q1 2026, $78.1 million in Q4 2025, and $71.3 million in Q3 2025.